Literature DB >> 22731513

What is special about patients with lung cancer and pulmonary metastases in palliative care? Results from a nationwide survey.

Bernd Alt-Epping1, Anke E Stäritz, Steffen T Simon, Nadine Altfelder, Thomas Hotz, Gabriele Lindena, Friedemann Nauck.   

Abstract

BACKGROUND: Patients with advanced lung cancer constitute a special focus in palliative care not only for epidemiological or prognostic reasons, but also because their symptom burden is felt to be widespread and difficult to treat. This study describes disease-specific characteristics and the symptom burden of patients with advanced incurable lung cancer, comparing them with patients suffering from other diseaseentities.
METHODS: A secondary analysis of the nationwide Hospice and Palliative Care Evaluation (HOPE) was performed, by focussing on inpatient hospice and palliative care unit patients and by using descriptive methods.
RESULTS: From 2006 to 2008, 5487 inpatients were registered, 874 of which were diagnosed with lung cancer and 1884 with pulmonary metastases. Symptoms such as weakness, tiredness, or pain were most prevalent in all subgroups. Dyspnea was significantly more prevalent in all patients with different kinds of pulmonary tumor manifestations; confusion was significantly more prevalent in patients with lung cancer. Dyspnea could not be treated as effectively as pain or nausea. Confusion and nursing problems worsened during the observation period. Dyspnea and confusion were associated with increased risk of death during the observational period.
CONCLUSION: The symptom pattern of patients with lung cancer is characterized by dyspnea and confusion--symptoms that are difficult to treat until discharge and that imply a worse prognosis. Therefore, increased research on the pathophysiology and treatment of dyspnea and confusion is required, and efforts in advance care planning and anticipation of dyspnea and confusion as a critical symptom in patients with lung cancer should be reinforced.

Entities:  

Mesh:

Year:  2012        PMID: 22731513     DOI: 10.1089/jpm.2011.0434

Source DB:  PubMed          Journal:  J Palliat Med        ISSN: 1557-7740            Impact factor:   2.947


  6 in total

1.  Imaging and Clinical Characteristics Predict Near-Term Disablement From Bone Metastases: Implications for Rehabilitation.

Authors:  Andrea L Cheville; Naveen S Murthy; Jeffrey R Basford; Peter S Rose; Kenny Tran; Thomas P Pittelkow; Michael D Ringler
Journal:  Arch Phys Med Rehabil       Date:  2015-10-03       Impact factor: 3.966

2.  Intranasal fentanyl for respiratory distress in children and adolescents with life-limiting conditions.

Authors:  Lucas Pieper; Julia Wager; Boris Zernikow
Journal:  BMC Palliat Care       Date:  2018-09-10       Impact factor: 3.234

3.  "I can't get it into my head that I have cancer…"-A qualitative interview study on needs of patients with lung cancer.

Authors:  Henrikje Stanze; Nils Schneider; Friedemann Nauck; Gabriella Marx
Journal:  PLoS One       Date:  2019-05-14       Impact factor: 3.240

4.  Continuous professional development: elevating thoracic oncology education in Europe.

Authors:  Wouter H van Geffen; Torsten G Blum; Stefano Aliberti; Kevin G Blyth; Clementine Bostantzoglou; Amy Farr; Bogdan Grigoriu; Georgia Hardavella; Rudolf M Huber; Nick Maskell; Gilbert Massard; Najib M Rahman; Daiana Stolz; Jan van Meerbeeck
Journal:  Breathe (Sheff)       Date:  2019-12

5.  "Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study".

Authors:  Brett C Bade; Geliang Gan; Fangyong Li; Lingeng Lu; Lynn Tanoue; Gerard A Silvestri; Melinda L Irwin
Journal:  BMC Cancer       Date:  2021-04-01       Impact factor: 4.430

6.  Sequential occurrence of dyspnea at the end of life in palliative care, according to the underlying cancer.

Authors:  Frédéric Guirimand; Marine Sahut d'izarn; Lucy Laporte; Marie Francillard; Jean-François Richard; Philippe Aegerter
Journal:  Cancer Med       Date:  2015-01-30       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.